{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:09:58Z","timestamp":1777504198623,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013318","name":"Shanxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27149","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T02:44:24Z","timestamp":1709001864000},"page":"e27149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt\/\u03b2-catenin signaling"],"prefix":"10.1016","volume":"10","author":[{"given":"Min","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunpeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinrui","family":"Suo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weie","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e27149_bib1","first-page":"316","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e27149_bib2","first-page":"1","volume":"5","author":"Carbone","year":"2019","journal-title":"Follicular lymphoma"},{"key":"10.1016\/j.heliyon.2024.e27149_bib3","first-page":"2516","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the","volume":"33","author":"Casulo","year":"2015","journal-title":"National LymphoCare Study"},{"key":"10.1016\/j.heliyon.2024.e27149_bib4","first-page":"3424","volume":"122","author":"Kridel","year":"2012","journal-title":"Pathogenesis of follicular lymphoma"},{"key":"10.1016\/j.heliyon.2024.e27149_bib5","first-page":"5044","volume":"23","year":"2005","journal-title":"Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin\u2019s Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e27149_bib6","first-page":"1174","volume":"27","author":"Goldman","year":"2013","journal-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report"},{"key":"10.1016\/j.heliyon.2024.e27149_bib7","first-page":"13","article-title":"Transcription, two faces of BRD4","volume":"4","author":"Dinah","year":"2013","journal-title":"Mitotic bookmark and transcriptional lynchpin"},{"key":"10.1016\/j.heliyon.2024.e27149_bib8","first-page":"2419","article-title":"Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer","volume":"4","author":"Wyce","year":"2013"},{"key":"10.1016\/j.heliyon.2024.e27149_bib9","first-page":"246","volume":"vol. 18","author":"Fujisawa","year":"2017"},{"key":"10.1016\/j.heliyon.2024.e27149_bib10","first-page":"3336","article-title":"PFI-1, a highly selective protein interaction inhibitor","volume":"73","author":"Picaud","year":"2013","journal-title":"targeting BET Bromodomains"},{"key":"10.1016\/j.heliyon.2024.e27149_bib11","first-page":"1797","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016"},{"key":"10.1016\/j.heliyon.2024.e27149_bib12","first-page":"237","article-title":"A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b","volume":"164","author":"Liang","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e27149_bib13","first-page":"594","article-title":"LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt\/\u03b2-catenin signaling pathway","volume":"510","author":"Shi","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e27149_bib14","first-page":"1461","volume":"36","author":"Zhan","year":"2017","journal-title":"Wnt signaling in cancer"},{"key":"10.1016\/j.heliyon.2024.e27149_bib15","first-page":"1","article-title":"oncology, Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e27149_bib16","volume":"vol. 160","author":"Zhang","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e27149_bib17","first-page":"9831","article-title":"Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a","volume":"55","author":"Fish","year":"2012","journal-title":"fragment-derived hit"},{"key":"10.1016\/j.heliyon.2024.e27149_bib18","first-page":"1","volume":"106","author":"Ferri","year":"2016","journal-title":"Bromodomains: Structure, function and pharmacology of inhibition"},{"key":"10.1016\/j.heliyon.2024.e27149_bib19","first-page":"13141","volume":"282","author":"Wu","year":"2007","journal-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation"},{"key":"10.1016\/j.heliyon.2024.e27149_bib20","first-page":"343","article-title":"The BET-inhibitor PFI-1 diminishes AR\/AR-V7 signaling in prostate cancer cells","volume":"37","author":"Hupe","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e27149_bib21","first-page":"259","article-title":"Evaluation of chidamide and PFI-1 as a combination therapy for triple-negative breast cancer","volume":"19","author":"Lin","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e27149_bib22","volume":"vol. 60","author":"Lui","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e27149_bib23","first-page":"2155","article-title":"BET inhibition-induced GSK3\u03b2 feedback enhances lymphoma vulnerability to PI3K inhibitors","volume":"24","author":"Derenzini","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e27149_bib24","volume":"vol. 60","author":"Lui","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e27149_bib25","article-title":"Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells","author":"Hultmark","year":"2020","journal-title":"Haematol."},{"key":"10.1016\/j.heliyon.2024.e27149_bib26","first-page":"985","article-title":"Wnt\/\u03b2-catenin signaling","volume":"169","author":"Nusse","year":"2017","journal-title":"disease, and emerging therapeutic modalities"},{"key":"10.1016\/j.heliyon.2024.e27149_bib27","series-title":"Targeting the Wnt\/\u03b2-Catenin Signaling Pathway in Cancer","author":"Patergnani","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e27149_bib28","first-page":"1185","article-title":"Discovery of small molecule inhibitors of the Wnt\/\u03b2-catenin signaling pathway by targeting \u03b2-catenin","volume":"242","author":"Yan","year":"2017","journal-title":"Tcf4 interactions"},{"key":"10.1016\/j.heliyon.2024.e27149_bib29","first-page":"431","volume":"55","author":"Xu","year":"2016","journal-title":"\u03b2\u2010catenin regulates c\u2010Myc and CDKN1A expression in breast cancer cells"},{"key":"10.1016\/j.heliyon.2024.e27149_bib30","first-page":"4847","article-title":"Cyr61 suppresses the growth of non-small-cell lung cancer cells via the \u03b2-catenin\u2013c-myc\u2013p53 pathway","volume":"23","author":"Tong","year":"2004"},{"key":"10.1016\/j.heliyon.2024.e27149_bib31","article-title":"PRMT7 promotes the growth of renal cell carcinoma through modulating the \u03b2-catenin\/C-MYC","volume":"120","author":"Liu","year":"2020","journal-title":"Axis"},{"key":"10.1016\/j.heliyon.2024.e27149_bib32","first-page":"6829","article-title":"FNC, a novel nucleoside analogue, blocks invasion of aggressive non-Hodgkin lymphoma cell lines via inhibition of the Wnt\/\u03b2-catenin signaling pathway","volume":"15","author":"Zhang","year":"2014"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024031803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024031803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:32:07Z","timestamp":1769045527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024031803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024031803"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27149","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt\/\u03b2-catenin signaling","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27149"}}